Compare LSBK & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | TLSA |
|---|---|---|
| Founded | 1891 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 145.1M |
| IPO Year | 2025 | 2017 |
| Metric | LSBK | TLSA |
|---|---|---|
| Price | $18.59 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.5K | ★ 936.5K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 49.23 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $0.87 |
| 52 Week High | $18.13 | $2.35 |
| Indicator | LSBK | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 83.88 | 42.33 |
| Support Level | $17.01 | $0.90 |
| Resistance Level | N/A | $1.20 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 83.06 | 15.59 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.